27.24
-1.00 (-3.54%)
| Penutupan Terdahulu | 28.24 |
| Buka | 28.00 |
| Jumlah Dagangan | 386,025 |
| Purata Dagangan (3B) | 582,435 |
| Modal Pasaran | 1,021,168,960 |
| Harga / Pendapatan (P/E Ke hadapan) | 46.73 |
| Harga / Jualan (P/S) | 4.54 |
| Harga / Buku (P/B) | 82.92 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Nov 2026 |
| Margin Keuntungan | -10.19% |
| Margin Operasi (TTM) | -23.48% |
| EPS Cair (TTM) | -0.610 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 38.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 410.02% |
| Nisbah Semasa (MRQ) | 0.910 |
| Aliran Tunai Operasi (OCF TTM) | 2.09 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.88 M |
| Pulangan Atas Aset (ROA TTM) | 0.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Harrow, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -5.0 |
| AI Insight | NA |
| Purata | -0.71 |
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 15.07% |
| % Dimiliki oleh Institusi | 57.11% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |